Chlormadinone acetate(プロスタール錠25)の前立腺肥大症に対する臨床効果の検討

Abstract

The clinical effect of chlormadinone acetate (Tab. Prostal(R)-25) as an anti-androgenic agent was studied by administering the drug to a total of 14 patients (12 outpatients and 2 inpatients) diagnosed as having benign prostatic hypertrophy at the Osaka University Hospital. 1. Change in subjective symptoms The subjective symptoms of the patients after the administration of this drug for 16 weeks were as follows: improvement in 7 cases (50.0%), slight improvement in 1 case (7.1%), no change in 5 cases (35.7%) and aggravation in 1 case (7.1%). In cases showing symptomatic improvement, it was recognized that the symptoms of those patients disappeared or were eased 2 to 4 weeks after the administration. 2. Change in residual urine volume After the administration of this drug for 16 weeks, the residual urine volume was decreased in 9 cases (64.3%), unchanged in 2 cases (14.3%) and increased in 3 cases (2l.4%). 3. Change in urethrocystogram The x-ray findings was made 16 weeks after the administration of this drug and the reduction of the length of prostatic urethra was noted in 9 cases (64.3%) as indicated below: markedly reduced ......... 6 cases (42.9%) slightly reduced ......... 3 cases (21.4%) In the remaining 5 cases (35.7%) the reduction was not found, but no cases showed further enlargement of adenoma. 4. General judgement In the general judgement, "excellent improvement" and "good improvement" were recognized in 8 cases (57.1%). As for the subjective symptoms, no remarkable improvement was obtained in this study so that the general judgement was based mainly on the residual urine volume and the x-ray findings. Therefore, the improvement rate almost corresponded to the results of x-ray findings. In other words, it can be said that the improvement in the clinical symptoms depends upon the effect of this drug for reducing the adenoma. 5. Side effect All through the administration period there were no subjective symptoms that were considered as side effects, but slight variations in the results of clinical examination were observed. Therefore, when this drug is administered for a long period, it is desirable to conduct general clinical examination in a proper manner. From the above results, Tab. Prostal-25 as an agent for prostatic hypertrophy has been evaluated to be a conservative remedy that is the most effective and useful among the agents used for this disease, as reported by Katayama et aI., although it is not so powerful that surgical operation is excluded from the treatment of prostatic hypertrophy.